Hepatocellular carcinoma primary prevention: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
Line 7: Line 7:


==Prevention==
==Prevention==
Hepatocellular carcinoma can be prevented by:<ref name="pmid23451000">{{cite journal |vauthors=Wiegand J, Berg T |title=The etiology, diagnosis and prevention of liver cirrhosis: part 1 of a series on liver cirrhosis |journal=Dtsch Arztebl Int |volume=110 |issue=6 |pages=85–91 |year=2013 |pmid=23451000 |pmc=3583179 |doi=10.3238/arztebl.2013.0085 |url=}}</ref>  
Hepatocellular carcinoma can be prevented by:<ref name="pmid19759364">{{cite journal |vauthors=Chang MH, You SL, Chen CJ, Liu CJ, Lee CM, Lin SM, Chu HC, Wu TC, Yang SS, Kuo HS, Chen DS |title=Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study |journal=J. Natl. Cancer Inst. |volume=101 |issue=19 |pages=1348–55 |year=2009 |pmid=19759364 |doi=10.1093/jnci/djp288 |url=}}</ref><ref name="pmid23451000">{{cite journal |vauthors=Wiegand J, Berg T |title=The etiology, diagnosis and prevention of liver cirrhosis: part 1 of a series on liver cirrhosis |journal=Dtsch Arztebl Int |volume=110 |issue=6 |pages=85–91 |year=2013 |pmid=23451000 |pmc=3583179 |doi=10.3238/arztebl.2013.0085 |url=}}</ref><ref name="pmid25995680">{{cite journal |vauthors= |title=2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma |journal=Korean J Radiol |volume=16 |issue=3 |pages=465–522 |year=2015 |pmid=25995680 |pmc=4435981 |doi=10.3348/kjr.2015.16.3.465 |url=}}</ref><ref name="pmid11575982">{{cite journal |vauthors=Kuffner EK, Dart RC, Bogdan GM, Hill RE, Casper E, Darton L |title=Effect of maximal daily doses of acetaminophen on the liver of alcoholic patients: a randomized, double-blind, placebo-controlled trial |journal=Arch. Intern. Med. |volume=161 |issue=18 |pages=2247–52 |year=2001 |pmid=11575982 |doi= |url=}}</ref><ref name="pmid3565791">{{cite journal |vauthors=Mazoit JX, Sandouk P, Zetlaoui P, Scherrmann JM |title=Pharmacokinetics of unchanged morphine in normal and cirrhotic subjects |journal=Anesth. Analg. |volume=66 |issue=4 |pages=293–8 |year=1987 |pmid=3565791 |doi= |url=}}</ref><ref name="pmid17970833">{{cite journal |vauthors=Wörns MA, Teufel A, Kanzler S, Shrestha A, Victor A, Otto G, Lohse AW, Galle PR, Höhler T |title=Incidence of HAV and HBV infections and vaccination rates in patients with autoimmune liver diseases |journal=Am. J. Gastroenterol. |volume=103 |issue=1 |pages=138–46 |year=2008 |pmid=17970833 |doi=10.1111/j.1572-0241.2007.01609.x |url=}}</ref><ref name="pmid15940414">{{cite journal |vauthors=Chu CM, Liaw YF |title=Increased incidence of fulminant hepatic failure in previously unrecognized HBsAg carriers with acute hepatitis independent of etiology |journal=Infection |volume=33 |issue=3 |pages=136–9 |year=2005 |pmid=15940414 |doi=10.1007/s15010-005-4094-4 |url=}}</ref><ref name="pmid21540206">{{cite journal |vauthors=Eckman MH, Kaiser TE, Sherman KE |title=The cost-effectiveness of screening for chronic hepatitis B infection in the United States |journal=Clin. Infect. Dis. |volume=52 |issue=11 |pages=1294–306 |year=2011 |pmid=21540206 |pmc=3097367 |doi=10.1093/cid/cir199 |url=}}</ref><ref name="pmid9462221">{{cite journal |vauthors=Bellentani S, Saccoccio G, Costa G, Tiribelli C, Manenti F, Sodde M, Saveria Crocè L, Sasso F, Pozzato G, Cristianini G, Brandi G |title=Drinking habits as cofactors of risk for alcohol induced liver damage. The Dionysos Study Group |journal=Gut |volume=41 |issue=6 |pages=845–50 |year=1997 |pmid=9462221 |pmc=1891602 |doi= |url=}}</ref><ref name="pmid23343065">{{cite journal |vauthors=Friedmann PD |title=Clinical practice. Alcohol use in adults |journal=N. Engl. J. Med. |volume=368 |issue=4 |pages=365–73 |year=2013 |pmid=23343065 |doi=10.1056/NEJMcp1204714 |url=}}</ref><ref name="pmid12799931">{{cite journal |vauthors=Tegeder I, Geisslinger G, Lötsch J |title=[Therapy with opioids in liver or renal failure] |language=German |journal=Schmerz |volume=13 |issue=3 |pages=183–95 |year=1999 |pmid=12799931 |doi=10.1007/s004829900019 |url=}}</ref><ref name="pmid7657281">{{cite journal |vauthors=Zimmerman HJ, Maddrey WC |title=Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure |journal=Hepatology |volume=22 |issue=3 |pages=767–73 |year=1995 |pmid=7657281 |doi= |url=}}</ref>  
** [[Alcohol]] cessation, especially in cirrhotic patients <ref name="pmid9462221">{{cite journal |vauthors=Bellentani S, Saccoccio G, Costa G, Tiribelli C, Manenti F, Sodde M, Saveria Crocè L, Sasso F, Pozzato G, Cristianini G, Brandi G |title=Drinking habits as cofactors of risk for alcohol induced liver damage. The Dionysos Study Group |journal=Gut |volume=41 |issue=6 |pages=845–50 |year=1997 |pmid=9462221 |pmc=1891602 |doi= |url=}}</ref><ref name="pmid23343065">{{cite journal |vauthors=Friedmann PD |title=Clinical practice. Alcohol use in adults |journal=N. Engl. J. Med. |volume=368 |issue=4 |pages=365–73 |year=2013 |pmid=23343065 |doi=10.1056/NEJMcp1204714 |url=}}</ref>
** Vaccination for [[Hepatitis B]]
**Avoidance of hepatotoxic drugs<ref name="pmid3565791">{{cite journal |vauthors=Mazoit JX, Sandouk P, Zetlaoui P, Scherrmann JM |title=Pharmacokinetics of unchanged morphine in normal and cirrhotic subjects |journal=Anesth. Analg. |volume=66 |issue=4 |pages=293–8 |year=1987 |pmid=3565791 |doi= |url=}}</ref><ref name="pmid12799931">{{cite journal |vauthors=Tegeder I, Geisslinger G, Lötsch J |title=[Therapy with opioids in liver or renal failure] |language=German |journal=Schmerz |volume=13 |issue=3 |pages=183–95 |year=1999 |pmid=12799931 |doi=10.1007/s004829900019 |url=}}</ref><ref name="pmid7657281">{{cite journal |vauthors=Zimmerman HJ, Maddrey WC |title=Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure |journal=Hepatology |volume=22 |issue=3 |pages=767–73 |year=1995 |pmid=7657281 |doi= |url=}}</ref><ref name="pmid11575982">{{cite journal |vauthors=Kuffner EK, Dart RC, Bogdan GM, Hill RE, Casper E, Darton L |title=Effect of maximal daily doses of acetaminophen on the liver of alcoholic patients: a randomized, double-blind, placebo-controlled trial |journal=Arch. Intern. Med. |volume=161 |issue=18 |pages=2247–52 |year=2001 |pmid=11575982 |doi= |url=}}</ref>
** [[Alcohol]] cessation, especially in cirrhotic patients
**Avoidance of hepatotoxic drugs
** Physical exercise
** Physical exercise
** [[Smoking cessation]]<ref name="pmid21126792">{{cite journal |vauthors=Zein CO, Unalp A, Colvin R, Liu YC, McCullough AJ |title=Smoking and severity of hepatic fibrosis in nonalcoholic fatty liver disease |journal=J. Hepatol. |volume=54 |issue=4 |pages=753–9 |year=2011 |pmid=21126792 |pmc=3060962 |doi=10.1016/j.jhep.2010.07.040 |url=}}</ref>
** [[Smoking cessation]]<ref name="pmid21126792">{{cite journal |vauthors=Zein CO, Unalp A, Colvin R, Liu YC, McCullough AJ |title=Smoking and severity of hepatic fibrosis in nonalcoholic fatty liver disease |journal=J. Hepatol. |volume=54 |issue=4 |pages=753–9 |year=2011 |pmid=21126792 |pmc=3060962 |doi=10.1016/j.jhep.2010.07.040 |url=}}</ref>
Line 17: Line 18:
*** [[Copper]]  
*** [[Copper]]  
*** [[Iron]]  
*** [[Iron]]  
** Vaccination for [[Hepatitis B]]<ref name="pmid21540206">{{cite journal |vauthors=Eckman MH, Kaiser TE, Sherman KE |title=The cost-effectiveness of screening for chronic hepatitis B infection in the United States |journal=Clin. Infect. Dis. |volume=52 |issue=11 |pages=1294–306 |year=2011 |pmid=21540206 |pmc=3097367 |doi=10.1093/cid/cir199 |url=}}</ref><ref name="pmid17970833">{{cite journal |vauthors=Wörns MA, Teufel A, Kanzler S, Shrestha A, Victor A, Otto G, Lohse AW, Galle PR, Höhler T |title=Incidence of HAV and HBV infections and vaccination rates in patients with autoimmune liver diseases |journal=Am. J. Gastroenterol. |volume=103 |issue=1 |pages=138–46 |year=2008 |pmid=17970833 |doi=10.1111/j.1572-0241.2007.01609.x |url=}}</ref><ref name="pmid15940414">{{cite journal |vauthors=Chu CM, Liaw YF |title=Increased incidence of fulminant hepatic failure in previously unrecognized HBsAg carriers with acute hepatitis independent of etiology |journal=Infection |volume=33 |issue=3 |pages=136–9 |year=2005 |pmid=15940414 |doi=10.1007/s15010-005-4094-4 |url=}}</ref>
** Education about  [[hepatotoxins]] such as [[acetaminophen]]  
** Education about  [[hepatotoxins]] such as [[acetaminophen]]  
** Prevention of [[obesity]]
** Prevention of [[obesity]]
Line 35: Line 35:
{{WikiDoc Help Menu}}
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
{{WikiDoc Sources}}


[[Category:Disease]]
[[Category:Disease]]

Revision as of 03:16, 14 January 2018

Hepatocellular carcinoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes of Hepatocellular carcinoma

Differentiating Hepatocellular carcinoma from other Diseases

Epidemiology & Demographics

Risk Factors

Screening

Natural History, Complications & Prognosis

Diagnosis

Diagnostic study of choice

History and symptoms

Physical Examination

Lab Tests

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hepatocellular carcinoma primary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hepatocellular carcinoma primary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hepatocellular carcinoma primary prevention

CDC on Hepatocellular carcinoma primary prevention

Hepatocellular carcinoma primary prevention in the news

Blogs on Hepatocellular carcinoma primary prevention

Directions to Hospitals Treating Hepatocellular carcinoma

Risk calculators and risk factors for Hepatocellular carcinoma primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2]

Overview

Hepatitis B vaccine is recommended for all children to prevent the development of hepatitis B, which is a major risk factor for hepatocellular carcinoma. Other primary prevention strategies include abstinence from alcohol and screening for hemochromatosis.

Prevention

Hepatocellular carcinoma can be prevented by:[1][2][3][4][5][6][7][8][9][10][11][12]

References

  1. ↑ Chang MH, You SL, Chen CJ, Liu CJ, Lee CM, Lin SM, Chu HC, Wu TC, Yang SS, Kuo HS, Chen DS (2009). "Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study". J. Natl. Cancer Inst. 101 (19): 1348–55. doi:10.1093/jnci/djp288. PMID 19759364.
  2. ↑ Wiegand J, Berg T (2013). "The etiology, diagnosis and prevention of liver cirrhosis: part 1 of a series on liver cirrhosis". Dtsch Arztebl Int. 110 (6): 85–91. doi:10.3238/arztebl.2013.0085. PMC 3583179. PMID 23451000.
  3. ↑ "2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma". Korean J Radiol. 16 (3): 465–522. 2015. doi:10.3348/kjr.2015.16.3.465. PMC 4435981. PMID 25995680.
  4. ↑ Kuffner EK, Dart RC, Bogdan GM, Hill RE, Casper E, Darton L (2001). "Effect of maximal daily doses of acetaminophen on the liver of alcoholic patients: a randomized, double-blind, placebo-controlled trial". Arch. Intern. Med. 161 (18): 2247–52. PMID 11575982.
  5. ↑ Mazoit JX, Sandouk P, Zetlaoui P, Scherrmann JM (1987). "Pharmacokinetics of unchanged morphine in normal and cirrhotic subjects". Anesth. Analg. 66 (4): 293–8. PMID 3565791.
  6. ↑ Wörns MA, Teufel A, Kanzler S, Shrestha A, Victor A, Otto G, Lohse AW, Galle PR, Höhler T (2008). "Incidence of HAV and HBV infections and vaccination rates in patients with autoimmune liver diseases". Am. J. Gastroenterol. 103 (1): 138–46. doi:10.1111/j.1572-0241.2007.01609.x. PMID 17970833.
  7. ↑ Chu CM, Liaw YF (2005). "Increased incidence of fulminant hepatic failure in previously unrecognized HBsAg carriers with acute hepatitis independent of etiology". Infection. 33 (3): 136–9. doi:10.1007/s15010-005-4094-4. PMID 15940414.
  8. ↑ Eckman MH, Kaiser TE, Sherman KE (2011). "The cost-effectiveness of screening for chronic hepatitis B infection in the United States". Clin. Infect. Dis. 52 (11): 1294–306. doi:10.1093/cid/cir199. PMC 3097367. PMID 21540206.
  9. ↑ Bellentani S, Saccoccio G, Costa G, Tiribelli C, Manenti F, Sodde M, Saveria Crocè L, Sasso F, Pozzato G, Cristianini G, Brandi G (1997). "Drinking habits as cofactors of risk for alcohol induced liver damage. The Dionysos Study Group". Gut. 41 (6): 845–50. PMC 1891602. PMID 9462221.
  10. ↑ Friedmann PD (2013). "Clinical practice. Alcohol use in adults". N. Engl. J. Med. 368 (4): 365–73. doi:10.1056/NEJMcp1204714. PMID 23343065.
  11. ↑ Tegeder I, Geisslinger G, Lötsch J (1999). "[Therapy with opioids in liver or renal failure]". Schmerz (in German). 13 (3): 183–95. doi:10.1007/s004829900019. PMID 12799931.
  12. ↑ Zimmerman HJ, Maddrey WC (1995). "Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure". Hepatology. 22 (3): 767–73. PMID 7657281.
  13. ↑ Zein CO, Unalp A, Colvin R, Liu YC, McCullough AJ (2011). "Smoking and severity of hepatic fibrosis in nonalcoholic fatty liver disease". J. Hepatol. 54 (4): 753–9. doi:10.1016/j.jhep.2010.07.040. PMC 3060962. PMID 21126792.
  14. ↑ Lieber CS, Rubin E (1968). "Alcoholic fatty liver in man on a high protein and low fat diet". Am. J. Med. 44 (2): 200–6. PMID 5635674.
  15. ↑ Modi AA, Feld JJ, Park Y, Kleiner DE, Everhart JE, Liang TJ, Hoofnagle JH (2010). "Increased caffeine consumption is associated with reduced hepatic fibrosis". Hepatology. 51 (1): 201–9. doi:10.1002/hep.23279. PMC 2801884. PMID 20034049.
  16. ↑ Mendenhall CL, Anderson S, Weesner RE, Goldberg SJ, Crolic KA (1984). "Protein-calorie malnutrition associated with alcoholic hepatitis. Veterans Administration Cooperative Study Group on Alcoholic Hepatitis". Am. J. Med. 76 (2): 211–22. PMID 6421159.
  17. ↑ Wedemeyer H, Hofmann WP, Lueth S, Malinski P, Thimme R, Tacke F, Wiegand J (2010). "[ALT screening for chronic liver diseases: scrutinizing the evidence]". Z Gastroenterol (in German). 48 (1): 46–55. doi:10.1055/s-0028-1109980. PMID 20072996.
  18. ↑ Breitling LP, Claessen H, Drath C, Arndt V, Brenner H (2011). "Gamma-glutamyltransferase, general and cause-specific mortality in 19,000 construction workers followed over 20 years". J. Hepatol. 55 (3): 594–601. doi:10.1016/j.jhep.2010.12.029. PMID 21256904.
  19. ↑ Claessen H, Brenner H, Drath C, Arndt V (2010). "Gamma-glutamyltransferase and disability pension: a cohort study of construction workers in Germany". Hepatology. 51 (2): 482–90. doi:10.1002/hep.23324. PMID 19967717.
  20. ↑ Haring R, Wallaschofski H, Nauck M, Dörr M, Baumeister SE, Völzke H (2009). "Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase levels". Hepatology. 50 (5): 1403–11. doi:10.1002/hep.23135. PMID 19670414.
  21. ↑ Bell BP, Manos MM, Zaman A, Terrault N, Thomas A, Navarro VJ, Dhotre KB, Murphy RC, Van Ness GR, Stabach N, Robert ME, Bower WA, Bialek SR, Sofair AN (2008). "The epidemiology of newly diagnosed chronic liver disease in gastroenterology practices in the United States: results from population-based surveillance". Am. J. Gastroenterol. 103 (11): 2727–36, quiz 2737. doi:10.1111/j.1572-0241.2008.02071.x. PMID 18684170.



Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=Hepatocellular_carcinoma_primary_prevention&oldid=1429928"